William Maughan
Stock Analyst at Canaccord Genuity
(2.98)
# 1,504
Out of 4,711 analysts
24
Total ratings
54.17%
Success rate
56.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 → $171 | $113.08 | +51.61% | 13 | Nov 27, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $8.28 | +117.39% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $24.13 | +74.06% | 6 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $6.10 | +162.30% | 2 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $14.68 | +308.72% | 1 | Jul 6, 2022 |
BioNTech SE
Nov 27, 2024
Maintains: Buy
Price Target: $171 → $171
Current: $113.08
Upside: +51.61%
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $8.28
Upside: +117.39%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $24.13
Upside: +74.06%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $6.10
Upside: +162.30%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $14.68
Upside: +308.72%